1.Clinical research of prophylactic hepatic artery infusion chemotherapy af-ter curative resection in patients with pancreatic cancer
Liqin YAO ; Chengwu TANG ; Wenming FENG ; Ying BAO ; Yinyuan ZHENG
China Modern Doctor 2015;(3):77-79,83
Objective To explore the effect of prophylactic hepatic artery infusion chemotherapy (HAIC) on survival after curative resection in patients with primary pancreatic cancer. Methods A total of 106 patients with pancreatic cancer after pancreatectomy received 2 cycles of HAIC plus 4 cycles of systemic chemotherapy (HAIC) or 6 cycles of sys-temic chemotherapy alone (Control). Both the HAIC and systemic chemotherapy regimen consisted of 5-fluorouracil 1000 mg/m2 on day 1 and Gemcitabine 800 mg/m2 on day 1 and 8. The treatment was started on an average of 3 weeks after surgery and repeated every 4 weeks. The disease-free survival , overall survival and liver metastases-free survival were compared. Results Significant differences were found in 3-year overall survival (HAIC, 23.08 %; Control, 14.81%;P=0.0473) and liver metastases-free survival (HAIC, 80.77%;Control, 55.56%;P=0.0014). There was no significant difference in adverse effects between two groups. Conclusion HAIC effectively and safely prevented liver metastases and improved the prognosis of patients with pancreatic cancer after pancreatectomy.
2.Epidemiological analysis of newly diagnosed occupational pneumoconiosis in Guangxi Zhuang Autonomous Region from 2013 to 2022
Hengqiu LIANG ; Lexin ZHANG ; Xuedong CHEN ; Yongmei LONG ; Jing YANG ; Liqin BAO ; Shiwen HUANG
China Occupational Medicine 2024;51(4):472-475
Objective To analyze the epidemiological distribution of new occupational pneumoconiosis (hereinafter referred to as "pneumoconiosis") in Guangxi Zhuang Autonomous Region from 2013 to 2022. Methods Data of newly diagnosed pneumoconiosis cases reported in Guangxi Zhuang Autonomous Region from 2013 to 2022 were collected, and epidemiological characteristics were analyzed using descriptive analysis method. Results A total of 972 newly diagnosed pneumoconiosis cases were reported in Guangxi Zhuang Autonomous Region from 2013 to 2022. Except for mica pneumoconiosis, 12 other types of pneumoconiosis were reported. Most of the cases were males, accounting for 97.0%. The diagnosis age of the cases of 40-<60 years old accounted for 77.4%, and the dust exposure age<30 years of the cases accounted for 96.4%. Silicosis was the most common type of pneumoconiosis, followed by coal workers' pneumoconiosis, accounting for 64.6% and 27.9%, respectively. The cases of stage Ⅰ, Ⅱ and Ⅲ pneumoconiosis accounted for 77.7%, 14.9% and 7.4%, respectively. The regional distribution was mostly in Hechi City, accounting for 51.9%. Industry distribution was more common in non-ferrous metal mining, coal mining and washing industry, accounting for 64.9% in total. Most cases were reported in private enterprises and small to medium-sized enterprises, accounting for 53.7% and 76.6% respectively. The most common occupations were coal miners and drillers, accounting for 47.7% in total. Conclusion Newly diagnosed pneumoconiosis cases in Guangxi Zhuang Autonomous Region show certain clustering characteristics in terms of disease type, region, enterprise characteristics, and occupation distribution. The prevention and treatment of pneumoconiosis in small and medium-sized private enterprises in key areas and key industries should be strengthened, especially for workers over 40 years old and with less than 30 years of dust exposure.
3.Thiolated chitosan-modified PLA-PCL-TPGS nanoparticles as oral drug carrier for lung cancer chemotherapy
Liqin JIANG ; Chao ZHANG ; Hai WANG ; Liyun PANG ; Bao XIAO ; Xiaoli WANG
International Journal of Biomedical Engineering 2017;40(5):331-338
Objective To construct a novel thiolated chitosan modified poly(lactide-co-ε-caprolactone)-d-α-tocopheryl polyethylene glycol 1 000 succinate (PLA-PCL-TPGS) nanoparticle,and investigate the feasibility of its use as an oral carrier for lung cancer chemotherapy.Methods The PLA-PCL-TPGS random copolymer was synthesized and characterized.Then three types of nanoparticles from commercial PCL and PLA-PCL-TPGS random copolymer were prepared for oral carrier of paclitaxel,including 5% thiolated chitosan-modified PCL nanoparticles (CNPs),unmodified PLA-PCL-TPGS nanoparticles (UNPs),and 5% thiolated chitosan-modified PLA-PCL-TPGS nanoparticles (TNPs).The prepared nanoparticles were characterized in terms of size,Zeta potential,morphology,drug loading and encapsulation efficiency.The in vitro drug release profiles and cellular uptake of the nanoparticles by human lung cancer cell lines A549 cells were investigated,and cytotoxicity against A549 cells was also evaluated.The evened sac method was used for the measurement of transportation of paclitaxel across the intestine barrier.Results The field emission scanning electron microscopy results showed that the three types of paclitaxel-loaded nanoparticles were spherical with a diameter about 200 nm.The surface charge of PLA-PCL-TPGS nanoparticles was reversed from negative to positive charge after thiolated chitosan modification.The UNPs and TNPs achieved higher drug loading,encapsulation efficiency and drug release after 32 d than CNP (all P<0.05).The TNPs had significantly higher cell uptake efficiency than that of CNPs and UNPs (all P<0.05).In vitro cell viability studies showed advantages of TNPs over a clinically available paclitaxel injection in terms of cytotoxicity against A549 cells.Ex vivo absorption studies revealed that the TNPs can increase paclitaxel transport by opening tight junctions and bypassing the efflux pump of P-glycoprotein.Conclusion PLA-PCL-TPGS nanoparticles modified by thiolated chitosan can enhance the cellular uptake and cytotoxicity,which reveals a potential application for oral chemotherapy of lung cancer.